Market News & Trends
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. recently announced the completion of enrollment and dosing in all five Phase 1a SAD cohorts, all four MAD cohorts, and the food…
Tolebrutinib Phase 3 Data Demonstrates Benefit on Disability Progression in Multiple Sclerosis
The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with…
Upperton Continues Strategic Growth With the Appointment of Michael Mellor-Clark as Chief Commercial Officer
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with…
BDD Pharma Opens New GMP Manufacturing Facility
Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful inspection by the Medicines and…
Comanche Biopharma Announces Orphan Drug Designation for CBP-4888 in sFlt1-Mediated Preterm Preeclampsia
Comanche Biopharma Corp. recently announced the European Medicines Agency (EMA) has granted orphan drug designation for CBP-4888 for the treatment of sFlt1-mediated preterm preeclampsia. A…
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Recursion recently announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or…
Opus Genetics Announces 1-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial of Gene Therapy in Inherited Retinal Diseases
Opus Genetics, Inc. recently announced 1-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in a Phase 1/2 open-label…
Sever Announces New Head of Global Business Development & Marketing
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs (including Implants, Vaginal Rings and…
Veranova Welcomes Dr. Scott Zugel as Global VP of Analytical Research Development Operations
Veranova is proud to announce the appointment of Dr. Scott Zugel as Global Vice President of Analytical Research Development Operations. Dr. Zugel brings 25 years…
ADMA Biologics Statement on Tariffs
ADMA Biologics, Inc. recently provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations, commercialization…
ALX Oncology Receives IND Clearance From FDA for a Novel EGFR-Targeted ADC
ALX Oncology Holdings Inc. recently announced receipt of US FDA clearance for the Investigational New Drug (IND) application for ALX2004, the company’s potential best- and…
Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals Inc. recently announced that it has entered into an additional license and use agreement with Sarborg Limited to expand the scope of work…
Ethris & Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Ethris and Lonza reecently announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery that offer a promising…
Gattefossé Advances Animal Health Through Science & Innovation
Gattefossé mission, advancing science for well-being, reflects its core engagement: to provide expert, customized, and responsible solutions in Personal Care and Pharmaceuticals, including animal health.…
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital
MoonLake Immunotherapeutics recently announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in…
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of an Oral Once-Daily Treatment for Obstructive Sleep Apnea
Incannex Healthcare Inc recently announced it has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of…
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial & Advance Regenerative Cell Therapy Pipeline
Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an…
BASF Launches Aroma Ingredients With Reduced Product Carbon Footprints
BASF Aroma Ingredients has successfully launched L-Menthol FCC rPCF as its first product with a reduced Product Carbon Footprint (rPCF). Further rPCF product launches are…
Greenwich LifeSciences Announces Positive Immune Response Data From Phase 3 Clinical Trial
Greenwich LifeSciences, Inc. recently announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the…
Antag Therapeutics Initiates Phase 1a Trial of a First-in-Class GIPR Antagonist to Address Key Gaps in Obesity Treatment
Antag Therapeutics recently announced the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is…
